Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions

摘要: Despite effective antiretroviral therapy (ART) and undetectable HIV RNA in the plasma, latent replication-competent persists indefinitely long-lived cells. Cessation of ART results rebound from these persistent reservoirs. While this was thought to be an insurmountable obstacle viral eradication, recent cases suggest otherwise. To date one patient has been “cured” several others have able interrupt without for prolonged periods. These events sparked renewed interest developing strategies that will allow eradication infected individuals. We review current knowledge latency reservoir, describe potential utility emerging cancer therapeutics cure research with emphasis on pathways implicated reservoir persistence, outline opportunities challenges context clinical trial regulatory environment.